Dermata Therapeutics Inc (DRMA) Stock Analysis
Verdict: AVOID
Critical cash runway depletion and zero revenue make this a binary clinical bet; current cash only funds operations through late 2026.
Investment score: 38/100
Analysis as of
Is Dermata Therapeutics Inc stock worth reviewing? AI model thesis
DRMA is a clinical-stage biotechnology firm with no revenue and a cash runway of approximately 12 months. Despite a low P/B of 0.78x and optimistic analyst targets of $6.00, the extreme cash burn and micro-cap status present significant dilution risk. The model views recent price gains as technical noise rather than fundamental improvement.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Dermata Therapeutics Inc opportunities and risks
What speaks for DRMA
- Phase III Data Catalyst
What speaks against DRMA
- Near-Term Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| DRMA | n/a | 0.0x | 0.8x | 0.0% | 0.0% | -944.4% |
| GNPX | n/a | 0.0x | 1.1x | 0.0% | 0.0% | -1769.6% |
| LIMN | n/a | 0.0x | n/a | 0.0% | 0.0% | -422.8% |
| MBIO | n/a | 0.0x | 4.0x | 0.0% | 0.0% | -91.6% |
| BIAF | n/a | 0.7x | n/a | 22.1% | -280.6% | -288.8% |
| TCRT | n/a | 1693.2x | n/a | -6333.3% | -136966.7% | -63.5% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -288.8% |
Frequently asked questions about Dermata Therapeutics Inc (DRMA)
Is DRMA stock a good investment?
The cached TradeMates AI model rates Dermata Therapeutics Inc as AVOID with an investment score of 38/100. DRMA is a clinical-stage biotechnology firm with no revenue and a cash runway of approximately 12 months. Despite a low P/B of 0.78x and optimistic analyst targets of $6.00, the extreme cash burn and micro-cap status present significant dilution risk. The model views recent price gains as technical noise rather than fundamental improvement. This is algorithmic model output, not personal investment advice.
Is DRMA stock a buy?
The TradeMates model verdict for DRMA is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.